The role of macrolides in asthma: current evidence and future directions (Q38221824)

31 August 2017

title

The role of macrolides in asthma: current evidence and future directions (English)

1 reference

31 August 2017

0 references

Michael Robert Edwards

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948430 AND SRC:MED&resulttype=core&format=json

9 June 2020

Sebastian L Johnston

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948430 AND SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Ernie H C Wong

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948430 AND SRC:MED&resulttype=core&format=json

9 June 2020

James D Porter

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948430 AND SRC:MED&resulttype=core&format=json

9 June 2020

publication date

16 June 2014

1 reference

The Lancet. Respiratory medicine

31 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948430 AND SRC:MED&resulttype=core&format=json

9 June 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948430 AND SRC:MED&resulttype=core&format=json

9 June 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948430 AND SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

657-670

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948430 AND SRC:MED&resulttype=core&format=json

Erythromycin in local treatment of cutaneous bacterial infections

9 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Macrolide antibiotics for cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

The September epidemic of asthma exacerbations in children: a search for etiology

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Chlamydophila pneumoniae and Mycoplasma pneumoniae: a role in asthma pathogenesis?

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Macrolides and ketolides: azithromycin, clarithromycin, telithromycin

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Macrolides for chronic asthma

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Macrolides for the long-term management of asthma--a meta-analysis of randomized clinical trials.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Use of azithromycin and death from cardiovascular causes

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Azithromycin and the risk of cardiovascular death

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Complex phenotypes in asthma: current definitions

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Asthma: one hundred years of treatment and onward

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

The use of macrolide antibiotic substances in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Efficacy of troleandomycin in outpatients with severe, corticosteroid-dependent asthma.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

The effect of troleandomycin on methylprednisolone elimination

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Randomised controlled trial of azithromycin in smokers with asthma

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Azithromycin for bronchial asthma in adults: an effectiveness trial

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

A trial of clarithromycin for the treatment of suboptimally controlled asthma

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Clarithromycin targets neutrophilic airway inflammation in refractory asthma.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

The effect of telithromycin in acute exacerbations of asthma

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Effect of clarithromycin on acute asthma exacerbations in children: an open randomized study.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

1 reference

7 January 2021

Heterogeneity of chronic obstructive pulmonary disease: from phenotype to genotype

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Is there a role for macrolides in severe asthma?

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Neutrophils in asthma

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Neutrophilic inflammation in severe persistent asthma

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Potentially pathogenic bacteria cultured from the sputum of stable asthmatics are associated with increased 8-isoprostane and airway neutrophilia

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Elevated Levels of Soluble Adhesion Molecules in Serum of Patients With Diffuse Panbronchiolitis

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Elevated concentrations of defensins in bronchoalveolar lavage fluid in diffuse panbronchiolitis

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Laboratory diagnosis of Mycoplasma pneumoniae infection

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada).

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Comparison of laboratory diagnostic procedures for detection of Mycoplasma pneumoniae in community outbreaks

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Management of asthma: the current US and European guidelines

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Real-world effects of once vs greater daily inhaled corticosteroid dosing on medication adherence

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Azithromycin for prevention of exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Mechanisms of action and clinical application of macrolides as immunomodulatory medications

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Telithromycin and acute liver failure

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Diagnosis of asthma - a new approach

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Disagreement among common measures of asthma control in children

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Asthma Control Questionnaire in children: validation, measurement properties, interpretation

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Validation of a standardized version of the Asthma Quality of Life Questionnaire

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

The health economics of asthma and rhinitis. I. Assessing the economic impact

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

The influence of hospitalizations due to exacerbations or spontaneous pneumothoraxes on the quality of life, mental function and symptoms of depression and anxiety in patients with COPD or asthma

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Antibiotics for acute asthma

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Routine antibiotics in hospital management of acute asthma

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Anti-inflammatory activity of azithromycin as measured by its NF-kappaB, inhibitory activity

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Epithelial NF-κB orchestrates house dust mite-induced airway inflammation, hyperresponsiveness, and fibrotic remodeling

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Novel insights into immune and inflammatory responses to respiratory viruses

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

The role of macrophages in obstructive airways disease: chronic obstructive pulmonary disease and asthma

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-κB inhibition.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Azithromycin inhibits macrophage interleukin-1β production through inhibition of activator protein-1 in lipopolysaccharide-induced murine pulmonary neutrophilia.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Azithromycin alters macrophage phenotype

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Azithromycin distinctively modulates classical activation of human monocytes in vitro.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Azithromycin suppresses proliferation, interleukin production and mitogen-activated protein kinases in human peripheral-blood mononuclear cells stimulated with bacterial superantigen

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Azithromycin Inhibits IL-5 Production of T Helper Type 2 Cells from Asthmatic Children

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Valosin containing protein (VCP) interacts with macrolide antibiotics without mediating their anti-inflammatory activities.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Impairment of lysosomal functions by azithromycin and chloroquine contributes to anti-inflammatory phenotype

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Microbes and mucosal immune responses in asthma.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Asthma exacerbations: origin, effect, and prevention.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Evidence for a causal relationship between respiratory syncytial virus infection and asthma

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Effect of clarithromycin on rhinovirus-16 infection in A549 cells

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Macrolide antibiotics inhibit respiratory syncytial virus infection in human airway epithelial cells

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Azithromycin induces anti-viral responses in bronchial epithelial cells

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Role of deficient type III interferon-λ production in asthma exacerbations

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Effect of clarithromycin on experimental rhinovirus-16 colds: a randomized, double-blind, controlled trial

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Azithromycin does not improve disease course in hospitalized infants with respiratory syncytial virus (RSV) lower respiratory tract disease: a randomized equivalence trial

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Lung microbiome for clinicians. New discoveries about bugs in healthy and diseased lungs

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Disordered microbial communities in asthmatic airways

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Viruses and microbiome alterations

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Nasally administered Lactobacillus rhamnosus strains differentially modulate respiratory antiviral immune responses and induce protection against respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Microbiota regulates immune defense against respiratory tract influenza A virus infection

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Erythromycin, a peptidyltransferase effector

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Erythromycin, carbomycin, and spiramycin inhibit protein synthesis by stimulating the dissociation of peptidyl-tRNA from ribosomes

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

The pharmacokinetics of azithromycin in human serum and tissues

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Correlation of increased azithromycin concentrations with phagocyte infiltration into sites of localized infection

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Mucus hypersecretion in asthma: intracellular signalling pathways as targets for pharmacotherapy

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Clarithromycin inhibits interleukin-13-induced goblet cell hyperplasia in human airway cells

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Antibiotic prevention of acute exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Antimicrobial-associated QT interval prolongation: pointes of interest

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Macrolide therapy in respiratory viral infections

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Topographical continuity of bacterial populations in the healthy human respiratory tract

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

Sequencing the human microbiome in health and disease.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

British Thoracic Society guideline for non-CF bronchiectasis

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70107-9

7 January 2021

10.1016/S2213-2600(14)70107-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948430 AND SRC:MED&resulttype=core&format=json

9 June 2020

1 reference